# US 2026/0098081 A1 · Metabolic selection via the glycine-formate biosynthesis pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098081 A1
- Document ID: US20260098081A1
- Status: Published application
- Kind: A1
- Application number: 19/112,697
- Filed: 2023-09-29
- Published: 2026-04-09
- Earliest claimed: 2022-09-30
- Assignees: Sigma-Aldrich Co.
- Applicants: Sigma-Aldrich Co. LLC.
- Inventors: Samuel Peters; James Ravellette; David Razafsky; Jason A. Gustin; Trissa Borgschulte
- Web page: https://patentgrep.com/patent/US20260098081A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/85: for animal cells
- C07K 1/14: Extraction; Separation; Purification
- C12N 5/0682: {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609)}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 9/1014: {Hydroxymethyl-, formyl-transferases (2.1.2)}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Y 201/02001: Glycine hydroxymethyltransferase (2.1.2.1)
- C07K 2317/31: multispecific
- C12N 2510/02: Cells for production
- C12N 2510/04: Immortalised cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Serine Hydroxymethyltransferase 2 (SHMT2). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.

## Claims

### Claim 1

A method for producing a recombinant protein product, the process comprising
(a) providing a mammalian cell line engineered to have reduced or eliminated expression of endogenous serine hydroxymethyltransferase 2 (SHMT2);
(b) introducing into the mammalian cell line a polynucleotide, wherein the polynucleotide encodes a functional SHMT2 gene and the recombinant protein;
(c) culturing the cell line; and
(d) purifying the recombinant protein to form the recombinant protein product.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mammalian cell line of (a) further comprises reduced or eliminated expression of endogenous glutamine synthetase (GS), phosphoserine phosphatase (PSPH), dihydrofolate reductase (DHFR), P5C synthase (P5CS), asparaginase (ASPG), alanine transaminase (ALT) and/or asparagine synthetase (ASNS).

### Claim 3 (depends on 1)

The method of claim 1, wherein the endogenous SHMT2 expression is reduced or eliminated by inactivating the endogenous SHMT2 gene of the mammalian cell line.

### Claim 4 (depends on 1)

The method of claim 1, wherein the endogenous SHMT2 gene is inactivated using a targeting endonuclease-mediated genome modification technique.

### Claim 5 (depends on 4)

The method of claim 4, wherein the targeting endonuclease is a CRISPR ribonucleoprotein complex or a pair of zinc finger nucleases.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mammalian cell line is a Chinese hamster ovary (CHO) cell line, a baby hamster kidney (BHK) cell line, a NS0 mouse myeloma cell line, a HEK293 cell line, or a Vero African green monkey kidney cell line.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cell line is a CHO cell line cultured with or without glycine and/or formate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the recombinant protein product is chosen from an antibody, an antibody fragment, a vaccine, a growth factor, a cytokine, a hormone, or a clotting factor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antibody is a bispecific or multispecific antibody.

### Claim 10

A genetically engineered mammalian cell line for use in a biologic production system, wherein the mammalian cell line is engineered to have reduced or eliminated expression of endogenous SHMT2.

### Claim 11 (depends on 10)

The mammalian cell line of claim 10, wherein expression of SHMT2 is reduced or eliminated via inactivation of at least one allele of a chromosomal sequence encoding SHMT2.

### Claim 12 (depends on 11)

The mammalian cell line of claim 11, wherein one or more alleles of the chromosomal sequence encoding SHMT2 are inactivated.

### Claim 13 (depends on 10)

The mammalian cell line of claim 10, wherein the cell line is engineered to have reduced or eliminated expression of endogenous glutamine synthetase (GS), phosphoserine phosphatase (PSPH), dihydrofolate reductase (DHFR), P5C synthase (P5CS), asparaginase (ASPG), alanine transaminase (ALT) and/or asparagine synthetase (ASNS).

### Claim 14 (depends on 12)

The mammalian cell line of claim 12, wherein the chromosomal sequence is inactivated using a targeting endonuclease-mediated genome modification technique.

### Claim 15 (depends on 14)

The mammalian cell line of claim 14, wherein the targeting endonuclease is a ribonucleoprotein complex or a pair of zinc finger nucleases.

### Claim 16 (depends on 15)

The mammalian cell line of claim 15, wherein the non-human cell line is a Chinese hamster ovary (CHO) cell line, a baby hamster kidney (BHK) cell line, a NS0 mouse myeloma cell line, a HEK293 cell line, or a Vero African green monkey kidney cell line.

### Claim 17 (depends on 16)

The mammalian cell line of claim 16 wherein the cell line is a CHO cell line cultured with or without glycine and/or formate.

### Claim 18 (depends on 17)

The mammalian cell line of claim 17, in which cell viability, viable cell density, titer, growth rate, proliferation response, cell morphology, and/or general cell health are comparable to those of a non-engineered parental mammalian cell line.

### Claim 19 (depends on 10)

The mammalian cell line claim 10, further comprising at least one nucleic acid encoding a recombinant protein chosen from an antibody, an antibody fragment, a vaccine, a growth factor, a cytokine, a hormone, or a clotting factor.

### Claim 20 (depends on 19)

The mammalian cell line of claim 19, wherein the antibody is a bispecific or multispecific antibody.

### Claim 21

A polynucleotide comprising a nucleic acid sequence encoding a functional SHMT2 and at least one recombinant protein of interest.

### Claim 22

A polynucleotide comprising
a) a nucleic acid sequence encoding a functional SHMT2;
b) a nucleic acid sequence encoding a functional GS and/or ASNS; and
c) a nucleic acid sequence encoding a mutation in the ASNS and/or SHMT2 coding sequence that attenuates the activity of either one or both of the enzymes
d) a nucleic acid sequence encoding a recombinant protein of interest.
